Marrakech Investor Day: International Investors are Choosing Marrakech, One of the World’s Dream Destinations
7.4.2022 12:28:00 EEST | Business Wire | Press release
In collaboration with the International Finance Corporation (IFC) and the Swiss State Secretariat for Economic Affairs (SECO), the Marrakech-Safi Regional Center for Investment hosted the inaugural edition of the Marrakech Investor Day, a meaningful event designed to allow hundreds of investors to explore the fantastic advantages and new investment opportunities across Marrakech.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005464/en/
Global supply chain disruptions, recent geopolitical changes, and the “Green Production” requirement, coupled with the multiple free trade agreements that provide direct access to more than 1.3 billion consumers, have aptly positioned Marrakech as the sustainable alternative for investors around the world.
Marrakech is a captivating imperial city boasting a sub-tropical mild climate and beautiful landscapes that make it an unmissable tourist destination. Moreover, Morocco provides attractive advantages for investors from all over the world. These advantages include political stability, a geo-strategic location and direct access to Europe and Africa’s markets, an attractive business-friendly environment, a robust, modern infrastructure, and prestigious talents taught in two of Africa’s best universities, all combined with a unique lifestyle and improved quality of life.
Marrakech, a city at the forefront of sustainability
Driven by the unrelenting will of the King of Morocco, with a target to generate 52% of energy from renewable sources by 2030, Marrakech offers investors the opportunity to put a little “green” in their portfolios and decarbonize the world’s industries.
The event was also an opportunity to explore the cultural richness and diversity of Marrakech, which actively encourages and facilitates foreign investments in multiple sectors, such as the agribusiness, tourism, creative industries, renewable energy, logistics, offshoring, and ICT.
These investment opportunities were made possible thanks to multiple reforms and facilitation mechanisms, which offer several incentives to stimulate investment (up to 30% of the total investment amount), improve the business climate and the competitiveness of the private sector.
More than 50 non-double taxation agreements, the absence of restrictions in the percentage of share capital and the free repatriation of funds are also influential factors that enable the region to offer a particularly modern and attractive legal and fiscal environment.
As part of the Marrakech Investor Day’s events, international investors were given a first-hand demonstration of these advantages that promote ease of doing investments in Marrakech and enhance transparency, such as the dematerialization of customs procedures and the personalized support of the Marrakech-Safi Regional Center for Investment.
The event also featured a panel discussion on the data-related investment opportunities, followed by the Marrakech Investor Awards ceremony, designed to celebrate the regions’ key investors.
To relive the event, and learn more about investment opportunities in Marrakech, visit www.marrakechinvest.ma
About:
The Regional Investment Center of Marrakech-Safi is a public institution with a mission is to facilitate, support and promote investments in the Marrakech-Safi region.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005464/en/
Contact information
Hanaa Zouzaf
h.zouzaf@crimarrakech.ma
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
